European Cardiometabolic Therapeutics 2026: Diabetes, Heart Failure, Fibrosis, Renal

Denmark concentrates the directory’s insulin + GLP-1 + peptide-metabolic operators. Novo Nordisk Kalundborg runs API manufacturing + biologics processing + metabolic-disease supply at Novo Nordisk’s flagship Danish site, including insulin and GLP-1 production for the global Ozempic / Wegovy / Rybelsus (semaglutide) franchise plus next-generation obesity programmes. Zealand Pharma (Copenhagen) develops peptide therapeutics for metabolic disease with a pipeline including dapiglutide (long-acting GLP-1/GLP-2 dual agonist with obesity and inflammatory-bowel programmes), glepaglutide (long-acting GLP-2 analogue for short-bowel syndrome), survodutide (partnered with Boehringer Ingelheim, GLP-1/glucagon dual agonist for obesity + MASH, in late-stage development), and other metabolic-disease peptides. For sponsors evaluating European insulin or GLP-1 manufacturing partnership, or peptide-metabolic licensing, Denmark concentrates the directory-surfaced operators.

Sweden hosts the largest dedicated European cardiometabolic R&D site in the directory through AstraZeneca Gothenburg. AstraZeneca Gothenburg is one of the company’s three global R&D hubs and the cardiometabolic + translational discovery centre — running discovery + early development across cardiovascular, renal, metabolic, and respiratory indications. Around AstraZeneca, Stockholm hosts AnaCardio (heart failure contractile agents at clinical stage), Diamyd Medical (Type 1 diabetes precision immunotherapy with Diamyd antigen-specific therapy at Phase 3), and Calliditas Therapeutics (commercial Tarpeyo / Kinpeygo budesonide for IgA nephropathy + orphan renal/hepatic pipeline). Lund adds Camurus (long-acting drug delivery for cardiometabolic + addiction). Umeå hosts InfiCure Bio (preclinical anti-fibrotic CRO services).

European cardiovascular therapeutics span six directory-listed clinical-stage operators. Idorsia (Allschwil, Switzerland) runs cardiovascular + CNS small-molecule discovery + clinical development (Tryvio aprocitentan for hypertension approved by FDA in 2024). AnaCardio (Stockholm, Sweden) develops heart-failure contractile agents at clinical stage. Aplagon (Helsinki, Finland) runs cardiovascular thromboinflammation + vascular occlusion programmes. Acesion Pharma (Copenhagen, Denmark) develops small molecules for atrial fibrillation and arrhythmia. Cardior Pharmaceuticals (Hannover, Germany) develops RNA-targeting cardiovascular therapeutics + miRNA modulation for heart failure (acquired by Novo Nordisk in 2024 in a publicly disclosed deal up to ~€1 billion). Adamed Pharma (Pienkow, Poland) operates an integrated pharmaceutical R&D + manufacturing business with cardiology in its portfolio. The Polish Biotech Landscape 2026 brief covers Adamed in wider context.

Fibrosis is a directory-surfaced cardiometabolic-adjacent therapeutic theme with five operators. Galecto (Copenhagen, Denmark) runs a galectin-targeted small-molecule pipeline for fibrosis + oncology + inflammation programmes (historic galectin-3 and LOXL2 portfolio; verify pipeline currency directly with the company before engagement). Alentis Therapeutics (Basel, Switzerland) develops claudin-1-targeting antibody therapeutics for fibrosis + oncology indications. Calluna Pharma (Oslo, Norway) develops first-in-class antibody therapeutics for fibrosis + inflammatory disease. AlgiPharma (Sandvika, Norway) develops alginate oligomer therapeutics for cystic fibrosis + biofilm disruption + antimicrobial resistance. InfiCure Bio (Umeå, Sweden) provides preclinical anti-fibrotic in-vivo efficacy CRO services + chronic inflammation models.

Poland holds three directory operators with cardiometabolic activity. Bioton (Warsaw) runs insulin biomanufacturing and diabetes therapeutics at commercial scope — the Polish insulin manufacturer with biosimilar adjacency. Adamed Pharma (Pienkow, near Warsaw) runs integrated pharmaceutical R&D and manufacturing with cardiology + CNS + respiratory portfolios. Biotts (Wroclaw) develops transdermal drug delivery using its MTC-Y carrier technology with insulin and diabetes formulation programmes. PolTREG (Gdansk) runs T-regulatory cell therapy for Type 1 diabetes (alongside its multiple sclerosis programmes covered in the CNS brief). The Polish Biotech Landscape 2026 brief covers Polish pharma in detail.

Around the cardiometabolic therapeutics layer the directory surfaces a CRO + drug-delivery + diagnostics adjunct. Metabolic + cardiometabolic preclinical CRO services run through Gubra (Hørsholm, Denmark, metabolic disease models + peptide therapeutics CRO) and Charles River Laboratories Finland (Kuopio, neuroscience + general preclinical at Kuopio site). Drug-delivery operators relevant to cardiometabolic include Camurus (long-acting injection), Orexo (formulation), DelSiTech (silica-based controlled release), Ypsomed (autoinjectors + pens for insulin/GLP-1 administration), Gerresheimer (primary packaging + drug-delivery devices), Biotts (transdermal). Cardiology AI diagnostics: Ligence (Kaunas, echocardiography analysis software + cardiac imaging AI), Hemolens Diagnostics (Wroclaw, FFR-CT non-invasive cardiology). The Drug Discovery Services 2026, European Diagnostics Landscape 2026, and Polish Biotech Landscape 2026 briefs cover these adjacent layers.

Match the decision to the indication. Insulin + GLP-1 manufacturing or supply: Novo Nordisk Kalundborg (Denmark). Peptide-metabolic licensing or development partnership: Zealand Pharma (Copenhagen). Cardiometabolic R&D collaboration: AstraZeneca Gothenburg (Sweden). Heart failure clinical partnership: AnaCardio (Stockholm). RNA-targeting cardiovascular: Cardior Pharmaceuticals (Hannover, owned by Novo Nordisk since 2024). Atrial fibrillation small molecules: Acesion Pharma (Copenhagen). Cardiovascular thromboinflammation: Aplagon (Helsinki). Cardiovascular + CNS small-molecule discovery: Idorsia (Allschwil). Type 1 diabetes precision immunotherapy: Diamyd Medical (Stockholm). Type 1 diabetes T-reg cell therapy: PolTREG (Gdansk). Renal + hepatic orphan: Calliditas Therapeutics (Stockholm, commercial Tarpeyo). Insulin biosimilar manufacturing: Bioton (Warsaw). Fibrosis programmes: Galecto, Alentis, Calluna, AlgiPharma. Metabolic preclinical CRO: Gubra (Hørsholm). Insulin/GLP-1 drug-delivery devices: Ypsomed (Burgdorf). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.